Analyst Gil Blum from Needham maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report) and keeping the price target at $8.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Gil Blum has given his Buy rating due to a combination of factors that favor Taysha Gene Therapies over its competitor. The pivotal study design for Taysha’s TSHA-102 gene therapy appears more straightforward and potentially more successful than Neurogene’s NGN-401. While both studies aim to achieve similar developmental milestones, NGN-401’s study has a higher bar for success, requiring minimal improvement on the CGI-I scale, which could be more challenging to meet.
Additionally, the inclusion criteria for NGN-401 involve a younger patient population, which may introduce confounding factors due to spontaneous developmental improvements. In contrast, Taysha’s study focuses on an older age group, potentially reducing these variables. These considerations, along with the clinical data suggesting a high responder rate for TSHA-102, support the Buy rating and the $8 price target for Taysha Gene Therapies.
In another report released on June 20, Wells Fargo also maintained a Buy rating on the stock with a $7.50 price target.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TSHA in relation to earlier this year.